To help labs get the answers they so desperately need, The Dark Intelligence Group has launched the COVID-19 STAT Intelligence Briefings Service.
During this disruptive SARS-CoV-2 pandemic, TDIG has created this free intelligence service with a total focus on COVID-19 and everything labs need to meet the business challenges of the pandemic, including the latest on rapid molecular serology COVID-19 testing, with sources and supply chain updates; How labs are getting paid for COVID-19 by Medicare, Medicaid, and private health plans; and Daily updates on changes to federal regulations and directives from the FDA, CDC, and CMS.
COVID-19 STAT Intelligence Briefings service updates daily. It includes briefings, interviews with leading subject matter experts, podcasts and webinars, plus timely analysis of the daily changes in the pandemic.
It is all actionable information, supplemented with real-time national lab test dashboards fed with data from TDIG partners at XIFIN, Visiun, and hc1.com.
COVID-19 STAT Intelligence Briefings is also introducing twice-weekly conference calls, so attendees can hear updates from nationally known thought leaders and get critical questions answered on managing their laboratories during the SARS-CoV-2 outbreak.
Amgen's UPLIZNA receives US FDA approval
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Zydus Lifesciences enters licence and supply partnership with Formycon
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older
Bayer launches Phase IIa trial of BAY 3401016 for Alport Syndrome